Associate Professor, Psychiatry, Case Western Reserve University School of Medicine
Psychiatry
Dr. Keming Gao, MD
|
|
Give Review
Keming works in the field of Psychiatry. He studied medicine at Weifang Medical University . Dr. Keming Gao is a published doctor. He has 54 papers published. The most current publication "Corpus callosum atrophy associated with the degree of cognitive decline in patients with Alzheimer's dementia or mild cognitive impairment: A meta-analysis of the regi..." Doctor Keming Gao, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Corpus callosum atrophy associated with the degree of cognitive decline in patients with Alzheimer's dementia or mild cognitive impairment: A meta-analysis of the regi...
- Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and Anxiety severity in patients with major depressi...
- Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety Disorder and other ...
- PPAR-γ Agonism as a Modulator of Mood: Proof-of-Concept for Pioglitazone in Bipolar Depression.
- The relationship between neurotrophins and bipolar Disorder.
- Decreased interhemispheric coordination in treatment-resistant depression: a resting-state fMRI study.
- Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study.
- Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I Disorder.
- Abnormal resting-state cerebellar-cerebral functional connectivity in treatment-resistant depression and treatment sensitive depression.
- Risk for Adverse Events and Discontinuation Due To Adverse Events of Ziprasidone Monotherapy Relative to Placebo in the Acute Treatment of Bipolar Depression, Mania, a...
- Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode Schizophrenia.
- Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood Disorders? Role of QIDS-16-SR total score in predicting number of A...
- Right lateralized white matter abnormalities in first-episode, Drug-naive paranoid schizophrenia.
- Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar Disorder.
- Abnormal neural activity of brain regions in treatment-resistant and treatment-sensitive major depressive Disorder: a resting-state fMRI study.
- Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode Schizophrenia: a double-blind, randomized, placebo-controlled s...
- Classification of different therapeutic responses of major depressive Disorder with multivariate pattern analysis method based on structural MR scans.
- Altered white matter integrity in young adults with first-episode, treatment-naive, and treatment-responsive depression.
- Altered white matter integrity of forebrain in treatment-resistant depression: a diffusion tensor imaging study with tract-based spatial statistics.
- Use of insulin sensitizers for the treatment of major depressive Disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity.
- Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary.
- Safety and efficacy of olanzapine monotherapy in treatment-resistant Bipolar mania: a 12-week open-label study.
- Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive Disorder, and generalized anxiety dis...
- A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with t...
- Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive Bipolar I or II depression: a double-blind, randomized, placebo-controlled trial.
- Lamotrigine Adjunctive Therapy to Lithium and Divalproex in Depressed Patients with Rapid Cycling Bipolar Disorder and a Recent Substance Use Disorder: A 12-week, Doub...
- Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive Disorder,...
- Second-generation antipsychotics in major depressive Disorder: update and clinical perspective.
- Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms.
- Independent predictors for lifetime and recent substance use Disorders in patients with rapid-cycling bipolar Disorder: focus on anxiety Disorders.
- Medical comorbidity in bipolar Disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome.
- Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized...
- Predictors of Non-Stabilization during the Combination Therapy of Lithium and Divalproex in Rapid Cycling Bipolar Disorder: A Post-hoc Analysis of Two Studies.
- Atypical antipsychotics in primary generalized anxiety Disorder or comorbid with mood Disorders.
- Correlates of historical suicide attempt in rapid-cycling bipolar Disorder: a cross-sectional assessment.
- Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar Disorder.
- Medical and substance use comorbidity in bipolar Disorder.
- Update on quetiapine in the treatment of bipolar Disorder: results from the BOLDER studies.
- A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar Disorder and Co-occurring ...
- Clinical correlates of patients with rapid-cycling bipolar Disorder and a recent history of substance use Disorder: a subtype comparison from baseline data of 2 random...
- Differential interactions between comorbid anxiety Disorders and substance use Disorder in rapid cycling bipolar I or II Disorder.
- A review of sensitivity and tolerability of antipsychotics in patients with bipolar Disorder or schizophrenia: focus on somnolence.
- Antipsychotic-induced extrapyramidal side effects in bipolar Disorder and schizophrenia: a systematic review.
- Treatment-emergent mania in unipolar and Bipolar depression: focus on repetitive transcranial magnetic stimulation.
- Serotonergic raphe magnus cell discharge reflects ongoing autonomic and respiratory activities.
- Acute treatment of mania: an update on new medications.
- Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or Disorders: a review.
- Awareness under anesthesia during electroconvulsive therapy treatment.
- Typical and atypical antipsychotics in Bipolar depression.
- Newer treatment studies for Bipolar depression.
- Clinical highlights in Bipolar depression: focus on atypical antipsychotics.
- Antiepileptic drugs in mood-Disordered patients.
- Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar Disorder.
Schools
Weifang Medical College
Procedures Preformed
- Electroconvulsive Therapy (ECT)
- Psychiatric Medication Therapy
Conditions Treated
- Adjustment Disorder
- Alcoholism (Alcohol Dependence)
- Anxiety
- Bipolar Disorder
- View All
Doctors Specialties
- Psychiatry
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Medicare Advantage PFFS
- Choice Care PPO
- MedHealthInsurance
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- United Healthcare
Education
-
Case Western Reserve University - MetroHealth -
Weifang Medical University
Hospital
-
University Hospitals Case Medical Center
Drug Facts
| NPI NUMBER | 1003839713 | |
| NPPES Provider LastName | GAO | |
| NPPES Provider FirstName | KEMING | |
| NPPES Provider ZIPCode | 441061716 | |
| NPPES Provider State | OH | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 945.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003839713 |
| Last Name Of The Provider | GAO |
| First Name Of The Provider | KEMING |
| View All |
Similar Doctors
|
Dr. Susan L. Padrino, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Phillip J. Resnick, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lysette E. Ramos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jyoti Aneja, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Martha Sajatovic, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Priyanka Baweja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olumuyiwa A. Abdul, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent A. Izediuno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ming Ren |